George Medicines
George Medicines is a London-based biopharmaceutical company developing proprietary single-pill, multi-mechanism combination therapies for cardiometabolic diseases, with FDA-approved WIDAPLIK for hypertension and GMRx4 in Phase II for type 2 diabetes, commercialized globally via regional licensing partners.
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What George Medicines does
George Medicines is a late-stage biopharmaceutical company that develops single-pill, multi-mechanism combination therapies for cardiometabolic diseases, primarily hypertension and type 2 diabetes. The company's core technology reformulates established, off-patent drugs at novel ultra-low doses into proprietary fixed-dose combinations; its lead product GMRx2/WIDAPLIK combines telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker), and indapamide (thiazide-like diuretic) in three dose strengths, including two lower than any previously available single-pill combination. WIDAPLIK received FDA approval in June 2025 as the first and only triple-combination therapy approved for initial treatment of hypertension, supported by two pivotal Phase III trials published in The Lancet, JACC, and the NEJM, with additional evidence from the TRIDENT stroke outcomes trial showing a 39% relative risk reduction in recurrent intracerebral hemorrhage stroke. GMRx4, a triple-combination candidate for type 2 diabetes, is in Phase II development.
The company operates an asset-light, partner-led commercialization model under which it retains ownership of its formulations and grants exclusive regional licensing and supply agreements to established pharmaceutical companies responsible for regulatory submissions, marketing, sales, and distribution in their territories. As of mid-2026, six regional agreements are in place covering the US (Azurity Pharmaceuticals), Australia/New Zealand (Arrotex), Korea (Ahngook Pharmaceutical), Brazil (Biolab Farmacêutica), Canada/Mexico/Colombia/Central America (Bausch Health), and Southeast Asia (Orient EuroPharma). Revenue is generated through upfront licensing fees, regulatory and commercial milestone payments, and tiered royalties on sales. The company is a venture-backed spin-out from George Health, the commercial arm of The George Institute for Global Health, with Brandon Capital as a key institutional backer. Headcount is reported at 1-10 employees, with clinical, regulatory, and formulation operations outsourced to specialized partners including George Clinical, Imperial College London's ICTU, Piramal Pharma Solutions, and Pharmalex (Cencora).
George Medicines firmographics
Firmographics- Name
- George Medicines
- Legal name
- George Medicines Pty Limited
- Website
- https://george-medicines.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- George Medicines is a London-based biopharmaceutical company developing proprietary single-pill, multi-mechanism combination therapies for cardiometabolic diseases, with FDA-approved WIDAPLIK for hypertension and GMRx4 in Phase II for type 2 diabetes, commercialized globally via regional licensing partners.
- Ownership category
- akta.pro rank
George Medicines industry classification
Industry- Product category
- Cardiometabolic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where George Medicines is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
George Medicines business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Licensing Fees and Upfront Payments: George Medicines receives upfront licensing fees from regional partners upon execution of licensing and supply agreements for GMRx2 commercialization rights.
- Regulatory and Commercial Milestone Payments: Company is eligible for regulatory milestone payments upon approval and commercial milestone payments based on sales performance as specified in licensing agreements with regional partners.
- Tiered Royalties on Sales: Future recurring revenue stream through stepped/tiered royalty rates on sales of GMRx2 in licensed territories, providing ongoing revenue as product adoption grows.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
George Medicines product offering
Product offeringCore offering
George Medicines develops and commercializes innovative single-pill, multi-mechanism combination therapies that combine established medicines at novel low-dose strengths to treat cardiometabolic diseases. Its lead product WIDAPLIK (GMRx2) is an FDA-approved triple combination of telmisartan, amlodipine and indapamide for the treatment of hypertension, including as initial therapy. The company also has GMRx4 in Phase II development for type 2 diabetes. It commercializes via exclusive regional licensing and supply partnerships rather than direct sales.
Product overview
George Medicines develops innovative single-pill, multi-mechanism combinations of existing treatments for cardiometabolic diseases. The core product portfolio includes GMRx2/WIDAPLIK (a triple combination of telmisartan, amlodipine, and indapamide for hypertension, FDA-approved in 2025) and GMRx4 (a triple combination for type 2 diabetes in Phase II development). These fixed-dose combinations use lower doses of established medicines combined in single pills to improve efficacy, safety, and patient adherence compared to traditional multi-pill regimens.
Differentiator
Problem solved
Functional benefit
Brands
- WIDAPLIK: FDA-approved single pill combination treatment for hypertension containing telmisartan, amlodipine and indapamide
Products and services
- WIDAPLIK (GMRx2) FDA-approved single-pill triple combination therapy containing telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker) and indapamide (thiazide-like diuretic), available in three dose strengths: 10/1.25/0.625 mg; 20/2.5/1.25 mg; and 40/5/2.5 mg. Approved as initial therapy for hypertension in adults, and the first and only FDA-approved triple combination for initial hypertension treatment. Commercialized via regional licensing partners (Azurity Pharmaceuticals in the US).
- GMRx4 Single-pill triple combination candidate in Phase II development for first-line treatment of type 2 diabetes, combining three best-in-class type 2 diabetes treatments in an ultra-low-dose, single-pill formulation to deliver synergistic efficacy with improved tolerability and adherence.
Quantifiable outcome
- 39% relative risk reduction for recurrent stroke in patients with prior intracerebral hemorrhage
- +4 more outcomes
Companies that use George Medicines
Customer profileSegments3 records
Ideal customer profiles1 record
George Medicines technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
George Medicines partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, core and supporting.
- Arrotex PharmaceuticalsmajorExclusive licensing and supply agreement granting Arrotex exclusive rights to commercialize GMRx2 in Australia and New Zealand. Arrotex is Australia's largest pharmaceutical supplier by prescription volume. George Medicines receives upfront licensing fee, commercial milestones, and tiered royalties. Arrotex to seek TGA (Australia) and Medsafe (NZ) regulatory approvals.
- Ahngook Pharmaceutical Co. LtdmajorExclusive licensing and supply agreement granting Ahngook Pharm exclusive rights to seek regulatory approval and commercialize GMRx2 in Korea. George Medicines receives upfront licensing fee plus regulatory and commercial milestone payments, and stepped royalties on sales. Ahngook Pharm is responsible for seeking regulatory approval with support from George Medicines.
- Azurity PharmaceuticalsmajorExclusive licensing agreement for US commercialization of WIDAPLIK (GMRx2). Azurity holds rights to commercialize the FDA-approved triple combination hypertension treatment in the United States.
- Bausch HealthmajorExclusive licensing agreement for commercialization of GMRx2 in Canada, Mexico, Colombia, and Central America.
- Biolab FarmacêuticamajorExclusive licensing agreement for commercialization of GMRx2 in Brazil.
- Orient EuroPharmamajorExclusive licensing agreement for commercialization of GMRx2 in Southeast Asia.
- The George Institute for Global HealthcoreGeorge Medicines is a spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes. The company uses the Institute's research base and scientific expertise for late-stage development of single-pill combination therapies. The George Institute conducts investigator-initiated trials including the TRIDENT stroke outcomes trial.
- Piramal Pharma SolutionssupportingContract pharmaceutical partner providing formulation development services for George Medicines' pipeline candidates.
- George ClinicalsupportingClinical development partner providing clinical trial management services, particularly for the Phase III program across multiple countries.
- Imperial Clinical Trials Unit (ICTU) at Imperial College LondonsupportingAcademic partner collaborating on Phase III clinical trials, particularly the placebo-controlled trial expanded into the UK, and investigator-initiated studies.
- RemediumOnesupportingClinical research organization partner supporting trial operations in Sri Lanka and other South Asian regions.
- Pharmalex (Cencora)supportingClinical development partner providing regulatory and clinical development support services.
- MedisantésupportingGlobal innovator in medical IoT collaborating with George Medicines to enable seamless decentralized data collection in Phase III clinical trials through remote monitoring technology.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
George Medicines competitors and assessment
Company assessmentDirect peers
- Cipla: Cipla is a leading Indian generics manufacturer with a large portfolio of cardiovascular fixed-dose combinations, including its own polypill program for cardiovascular prevention. Highly comparable to George Medicines because it sells multi-drug FDCs targeting hypertension and cardiovascular disease, often at scale across emerging markets through licensing and partnerships.
- Ferrer Internacional: Ferrer commercializes Trinomia, a single-pill triple combination of aspirin, atorvastatin, and ramipril for secondary cardiovascular prevention. Closest direct comparable to George Medicines' WIDAPLIK given the explicit polypill/FDC architecture, cardiovascular indication, and partner-led commercialization model.
- Zydus Lifesciences: Zydus is an Indian pharma group with a deep cardiovascular generics and FDC franchise and a history of polypill development. Comparable because it competes in the same cardiometabolic FDC category and pursues similar single-pill combination strategies across global markets.
- Glenmark Pharmaceuticals: Glenmark has a substantial branded-generic cardiometabolic portfolio, including several fixed-dose combinations for hypertension and diabetes. Relevant direct peer as it competes with novel FDCs in similar patient segments and markets.
- Dr. Reddy's Laboratories: Dr. Reddy's combines generics with a branded cardiometabolic franchise across India, emerging markets and the US. Comparable to George Medicines in its emphasis on combination products and out-licensing for territory-specific commercialization.
- Sun Pharmaceutical Industries: Sun Pharma operates one of India's largest cardiology FDC portfolios alongside specialty and generics businesses. Direct peer because it sells competing single-pill combinations for hypertension and cardiovascular disease globally, including through regional licensing arrangements.
Broad incumbents
- AstraZeneca: AstraZeneca is a major incumbent in cardiovascular and cardiometabolic medicine with products like Brilinta, Crestor and a large hypertension and diabetes portfolio. Broadly comparable as a global cardiometabolic incumbent, and notable because George Medicines' current CEO Mark Mallon previously led AstraZeneca's international operations.
- Bayer: Bayer is a global incumbent in cardiovascular medicine with products such as Xarelto, Adempas, and Eylea. Comparable at the category level because it serves the same physician prescribers and hypertension/cardiovascular patients, though Bayer's portfolio is broader and not focused on FDCs.
- Novartis: Novartis is a major incumbent in cardiometabolic disease via Entresto, Leqvio, and a hypertension and diabetes portfolio. Comparable as a global cardiovascular player whose physician-facing commercial model and clinical evidence base set the benchmark George Medicines' partners must compete against.
- Viatris: Viatris is a large generics and branded pharma company with a deep cardiovascular franchise, including combinations targeting hypertension and lipid management. Comparable as a broad incumbent that George Medicines' licensing partners (e.g. Bausch Health) compete with in the cardiovascular generics and FDC space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
George Medicines social profiles
Digital presenceGeorge Medicines compliance and trust
Trust signalCompliance3 records
George Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
George Medicines leadership team
Management profileNumber of profiles
Profiles10 records
George Medicines subsidiaries and ownership
Company hierarchySubsidiaries1 record
George Medicines funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
George Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about George Medicines
What does George Medicines do?
George Medicines develops and commercializes innovative single-pill, multi-mechanism combination therapies that combine established medicines at novel low-dose strengths to treat cardiometabolic diseases. Its lead product WIDAPLIK (GMRx2) is an FDA-approved triple combination of telmisartan, amlodipine and indapamide for the treatment of hypertension, including as initial therapy. The company also has GMRx4 in Phase II development for type 2 diabetes. It commercializes via exclusive regional licensing and supply partnerships rather than direct sales.
Is George Medicines a public or private company?
George Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was George Medicines founded?
George Medicines was founded in 2021. It employs 1 to 10 people.
Where is George Medicines based?
George Medicines is headquartered in London, United Kingdom, in the Europe region.
How does George Medicines make money?
Three revenue lines are on record. Licensing Fees and Upfront Payments are the primary driver. The others are regulatory and Commercial Milestone Payments and tiered Royalties on Sales.
Who are George Medicines's main competitors?
Direct peers on record are Cipla, Ferrer Internacional, Zydus Lifesciences, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories and Sun Pharmaceutical Industries. Broad incumbents are AstraZeneca, Bayer, Novartis and Viatris.
Does George Medicines have an API?
No public API is recorded for George Medicines.
What industry is George Medicines in?
George Medicines's product category is Cardiometabolic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.